Cytomegalovirus Colitis Following Azacitidine Therapy

Khan, Rajal; Rudkin, Pam; Grewal, Kuljit; Leonard, Jennifer; Hamodat, Mowafak; Hutchinson, Jim; Daley, Peter

doi:10.1155/2011/616725

Cited by 5 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is increasing incidence of CMV reactivation in patients undergoing conventional chemotherapy. In our literature review, the earliest reported case of CMV colitis after standard chemotherapy was in a patient receiving azacitidine, published in 2011 [ 2 ]. A recent study involving 15 cancer patients with 11 head and neck cancers, two lung cancers, one lymphoma, and one rectal cancer showed that all but one patient experienced CMV reactivation during the course of chemotherapy [ 3 ].…”

Section: Discussionmentioning

confidence: 99%

Cytomegalovirus Colitis Masquerading as Apple-Core Lesion after Systemic Chemotherapy in a Patient with Relapsed Acute Myeloid Leukemia

Brownell

Barker

et al. 2018

Case Reports in Oncological Medicine

View full text Add to dashboard Cite

We report the case of a 71-year-old male with relapsed acute myeloid leukemia who developed cytomegalovirus (CMV) colitis presenting as an apple-core lesion during induction chemotherapy. CMV infection occurs rarely during induction chemotherapy for acute myeloid leukemia. CMV infection is usually observed in patients with acquired immune deficiency syndrome (AIDS) and in those on immunosuppressive agents following bone marrow transplant. Although rare, CMV colitis should be considered in patients who are critically ill after systemic chemotherapy as it can cause significant morbidity and mortality.

show abstract

Section: Discussionmentioning

confidence: 99%

Cytomegalovirus Colitis Masquerading as Apple-Core Lesion after Systemic Chemotherapy in a Patient with Relapsed Acute Myeloid Leukemia

Brownell

Barker

et al. 2018

Case Reports in Oncological Medicine

View full text Add to dashboard Cite

show abstract

“…A conforto del ruolo eziologico svolto dal CMV nell'esacerbazione della malattia, dati di letteratura riportano remissione della fase di riacutizzazione e riduzione della morbilità dopo trattamento dell'infezione con terapia antivirale (Ganciclovir o Foscarnet) (4,8). Analogamente, il nostro paziente, trattato con Ganciclovir per 15 gg., presentava, al termine della terapia, assenza di viremia su sangue e remissione della sintomatologia clinica (dolore addominale e rettorragia).…”

Section: Conclusioniunclassified

Reactivation of intestinal CMV in a renal transplant patient after 10 years from the transplant

Landi¹,

Simone²,

Nisco³

et al. 2013

Microbiol Med

View full text Add to dashboard Cite

Riattivazione di CMV a livello intestinale in paziente trapiantato renale a distanza di 10 anni dal trapianto SUMMARY Introduction. We analyzed the clinical case of a 51 years old man, kidney transplanted on December 2002. On April 2011, he had acute rectal bleeding, renal chronic rejection (creatinine 2.9 mg/dl), Hgb 8.7 g/dl, positive anti-CMV antibodies (IgG). A colonoscopy showed diverticulosis of the rectum associated with deepithelialisation.The patient was treated with maintenance immunosuppressive post-transplant therapy. On June 2011, the colonoscopy showed a stenosing lesion of the sigmoid colon, and blood sampling and intestinal biopsy were performed to search Cytomegalovirus (CMV) DNA by PCR. Methods. The presence of CMV-DNA was sought by automatic extractor QIACUBE, using QIAamp DNA BLOOD Mini Kit (Qiagen) for whole blood and QIAamp DNA Mini Kit (Qiagen) for biopsy.The extracted DNA was then amplified by Real Time PCR using Q-CMV RealTime Complete Kit (Nanogen), on instrument Applied Biosystems 7300. Results. At disease onset the viral load in whole blood was 208000 Geq/ml, and biopsy was positive. Antiviral therapy with Ganciclovir led to the negativity of the viral load and remission of symptoms. Conclusions. The clinical case described presented a reactivation of CMV infection in the intestine after more than 10 years from kidney transplantation, while the highest incidence of CMV reactivation usually occurs during the first year. In our opinion, the reactivation can be traced to long-term immunosuppressive therapy (maintenance posttransplant therapy) in combination with a state of inflammation of the intestinal mucosa. In fact, patients with IBD treated with steroid drugs, in particular the group of refractory to therapy and thus have a recovery of the inflammatory process, are exposed to reactivation of CMV with intestinal localization. Figura I. Cytomegalovirus.

show abstract

“…Here, we present a case of CMV colitis following treatment with azacitidine and venetoclax for acute myeloid leukaemia (AML). While reviewing the literature, we found only one prior case report mentioning the occurrence of CMV colitis following azacitidine single-agent administration [ 4 ]. However, it is important to highlight that CMV reactivation/disease is most likely an under-diagnosed condition in AML settings before HSCT, as previously reported [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

CMV Colitis: A Rare Complication of Azacitidine and Venetoclax Chemotherapy

et al. 2022

View full text Add to dashboard Cite

Herein, we present a case of cytomegalovirus (CMV) colitis that occurred after two cycles of azacitidine and venetoclax in a 64-year-old woman affected with acute myeloid leukaemia (AML) secondary to a previous diagnosis of a hypoplastic myelodysplastic syndrome (hypo-MDS). This patient never had detectable CMV viraemia, and there was no evidence of immune deficiency that could justify this opportunistic infection. Additionally, this is most likely the first report describing CMV colitis in a patient treated upfront with azacitidine and venetoclax.

show abstract

Cytomegalovirus Colitis Following Azacitidine Therapy

Cited by 5 publications

References 21 publications

Cytomegalovirus Colitis Masquerading as Apple-Core Lesion after Systemic Chemotherapy in a Patient with Relapsed Acute Myeloid Leukemia

Cytomegalovirus Colitis Masquerading as Apple-Core Lesion after Systemic Chemotherapy in a Patient with Relapsed Acute Myeloid Leukemia

Reactivation of intestinal CMV in a renal transplant patient after 10 years from the transplant

CMV Colitis: A Rare Complication of Azacitidine and Venetoclax Chemotherapy

Contact Info

Product

Resources

About